Predicting the complicated neutropenic fever in the emergency department

Emergency Medicine Journal

Volumn 26, Issue 11, 2009, Pages 802-806

  Moon, J M ^a   Chun, B J ^a  

^a Chonnam National University Medical School   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTINEOPLASTIC AGENT; C REACTIVE PROTEIN; CEFEPIME; CEFTAZIDIME; HEMOPOIETIC GROWTH FACTOR; IMIPENEM; MEROPENEM;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BLEEDING; CHEMOTHERAPY; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; EMERGENCY WARD; FEBRILE NEUTROPENIA; FEMALE; HEART ARRHYTHMIA; HEMATOLOGIC MALIGNANCY; HOSPITALIZATION; HUMAN; HYPOTENSION; KIDNEY FAILURE; LEUKEMIA; LUNG INFILTRATE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MENTAL DISEASE; MULTIPLE MYELOMA; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RESPIRATORY FAILURE; RISK ASSESSMENT; THORAX RADIOGRAPHY; THROMBOCYTE COUNT;

AGED; ANTINEOPLASTIC AGENTS; EMERGENCY SERVICE, HOSPITAL; FEMALE; FEVER; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RESPIRATORY INSUFFICIENCY;

EID: 70350438420     PISSN: 14720205     EISSN: 14720213     Source Type: Journal    
DOI: 10.1136/emj.2008.064865     Document Type: Article

References (22)

1. Talcott JA, Finberg R, Mayer RJ, et al. The medical course of cancer patients with fever and neturopenia. Clinical identification of a low risk subgroup at presentation. Arch Intern Med 1988;148:2561-2568
2. Schimpff SC. Empiric antibiotic therapy for granulocytopenic cancer patients. Am J Med 1986;80:13-20. (Pubitemid 16090510)
3. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low risk febrile neutropenic cancer patients. J Clin Oncol 2000;18:3038-3051 (Pubitemid 30644129)
4. Pizzo PA, Robichaud KJ, Gill FA, et al. Duration of empiric antibiotic therapy in granulocytopenic patients with cancer. Am J Med 1979;67:194-200.
5. Rolston KV, Manzullo EF, Elting LS, et al. Once daily, oral, outpatient quinolone monotherapy for low-risk cancer patients with fever and neutropenia: a pilot study based on validated risk prediction rules. Cancer 2006;106:2489-2494
6. Sebban C, Dussart S, Fuhrmann C, et al. Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge. Support Care Cancer 2008;16:1017-1023
7. Rackoff WR, Gonin R, Robinson C, et al. Predicting the risk of bacteremia in children with fever and neutropenia. J Clin Oncol 1996;14:919-924 (Pubitemid 26085537)
8. Viscoli C, Bruzzi P, Castagnola E, et al. Factors associated with bacteremia in febrile, granulocytopenic cancer patients. Eur J Cancer 1994;30A:430-437
9. Hubel K, Hegener K, Schnell R, et al. Suppressed neutrophil function as a risk factor for severe infection after cytotoxic chemotherapy in patients with acute nonlymphocytic leukemia. Ann Hematol 1999;78:73-77 (Pubitemid 29132437)
10. Jimeno A, Garcia-Velasco A, del Val O, et al. Assessment of procalcitonin as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia. Cancer 2004;100:2462-2469
11. Persson L, Soderquist B, Engervall P, et al. Assessment of systemic inflammation markers to differentiate a stable from deteriorating clinical course in patients with febrile neutropenia. Eur J Haematol 2005;74:297-303. (Pubitemid 40461149)
12. Uys A, Rapoport BL, Fickl H, et al. Prediction of outcome in cancer patients with febrile neutropenia: comparison of the Multinational Association of Supportive Care in Cancer risk-index score with procalcitonin, C reactive protein, serum amyloid A, and interleukins-1beta, -6, -8 and -10. Eur J Cancer Care 2007;16:475-483
13. Persson L, Engervall P, Magnuson A, et al. Use of inflammatory markers for early detection of bacteraemia in patients with febrile neturopenia. Scand J Infect Dis 2004;36:365-371 (Pubitemid 38967694)
14. Hughes WT, Armstrong D, Bodey GP, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-751 (Pubitemid 34194843)
15. Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotics management of the neutropenic patient. Report of a consensus panel. J Infect Dis 1990;161:397-401.
16. Baorto EP, Aquino VM, Mullen CA, et al. Clinical parameters associated with low bacteremia risk in 1100 pediatric oncology patients with fever and neutropenia. Cancer 2001;92:909-913
17. Klaassen RJ, Goodman TR, Pham B, et al. Low risk prediction rule for pediatric oncology patients presenting with fever and neutropenia. J Clin Oncol 2000;18:1012-1019 (Pubitemid 30123777)
18. Erten M, Genc S, Besisik SK, et al. The predictive and diagnostic values of procalcitonin and C-reactive protein for clinical outcome in febrile neutropenic patients. J Chin Med Assoc 2004;67:217-221 (Pubitemid 39069701)
19. Offidani M, Corvatta L, Malerba L, et al. Risk assessment of patients with hematologic malignancies who develop fever asscompanied by pulmonary infiltrates: a historical cohort study. Cancer 2004;101:567-577 (Pubitemid 38970608)
20. Heussel CP, Kauczor HU, Ullmann AJ. Pneumonia in neutropenic patients. Eur Radiol 2004;14:256-271
21. Sipsas NV, Bodey GP, Kontoyiannis DP. Perspectives for the management of febrile neutropenic patients with cancer in the 21st century. Cancer 2005;103:1103-1113 (Pubitemid 40328079)
22. Garcia-Carboner R, Paz-Aves L. Antibiotics and growth factors in the management of fever and neutropenia in cancer patients. Curr Opin Hematol 2002;9:215-221 (Pubitemid 34275967)